UNITY Biotechnology Scheduling Phase II Senolytics Trial for Late 2019

UNITY Biotechnologies is the furthest ahead of the growing number of companies working on the development of senolytic therapies capable of selectively destroying senescent cells in old tissues. Senescent cells are generated constantly in the body, but are near all destroyed by programmed cell death processes or by the immune system. The few that linger,...